HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · Real-Time Price · USD
1.110
-0.070 (-5.93%)
Mar 31, 2025, 10:41 AM EDT - Market open
HOOKIPA Pharma Revenue
In the year 2024, HOOKIPA Pharma had annual revenue of $43.95M with 118.32% growth. HOOKIPA Pharma had revenue of $1.35M in the quarter ending December 31, 2024, a decrease of -81.72%.
Revenue (ttm)
$43.95M
Revenue Growth
+118.32%
P/S Ratio
0.34
Revenue / Employee
$505,126
Employees
87
Market Cap
13.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
HOOK News
- 5 weeks ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) - GlobeNewsWire
- 2 months ago - Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Inc - FORM 8 (OPD) - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment - GlobeNewsWire
- 3 months ago - Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. - GlobeNewsWire
- 4 months ago - HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewsWire
- 5 months ago - HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - GlobeNewsWire